- Home
- Companies
- Global Access Diagnostics (GADx)
- Products
- Chronic Respiratory Diseases
Chronic Respiratory Diseases
Chronic respiratory diseases affect nearly 550 million people worldwide. Although these conditions are incurable, treatment is available to manage symptoms. Rapid diagnostic tests are crucial in the early detection of an exacerbation, thereby limiting the potential of unfavourable health consequences and improving the patient’s quality of life.
By the time symptoms appear, there is usually already significant lung damage. Respiratory infections further inflame the lungs, compromising breathing and causing further damage to lung tissue.
If these exacerbations can be predicted before the symptoms appear, they can be dealt with earlier, limiting their effect and the potential consequences. Being able to determine whether the inflammation is eosinophil or neutrophil-based can help to determine whether steroids or antibiotics are the best therapy.
Global Access Diagnostics (GADx) is currently developing rapid diagnostic tests for Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF). Early detection of exacerbation will enable health professionals and patients to determine whether the inflammation is eosinophil- or neutrophil-based; therefore, decide whether steroids or antibiotics are the best therapy.